Breaking News Instant updates and real-time market news.

NVS

Novartis

$84.77

1.5 (1.80%)

, CERU

Cerulean

$0.63

-0.0191 (-2.94%)

08:25
07/19/17
07/19
08:25
07/19/17
08:25

Cerulean to host special shareholder meeting

Special Shareholder Meeting to approve the Novartis Asset Sale Proposal and the Dare Share Issuance Proposal will beheld in Boston on July 19 at 9 am.

NVS

Novartis

$84.77

1.5 (1.80%)

CERU

Cerulean

$0.63

-0.0191 (-2.94%)

  • 19

    Jul

NVS Novartis
$84.77

1.5 (1.80%)

07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.
CERU Cerulean
$0.63

-0.0191 (-2.94%)

08/18/16
ROTH
08/18/16
NO CHANGE
Target $2.5
ROTH
Buy
Roth Capital trims Cerulean price target, but remains a buyer
Roth Capital analyst Joseph Pantginis lowered his price target for Cerulean to $2.50 from $9 after the company's Phase 2 clinical trial of CRLX101 for advanced renal cell carcinoma, or RCC, demonstrated no statistically significant difference. Nonetheless, with a platform technology providing long-term pipeline fill and improvements in tumor targeting, Pantginis believes Cerulean remains an attractive opportunity despite the failure in late-stage RCC. He reiterates a Buy rating on the shares.
08/18/16
08/18/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Sell from Hold at Evercore ISI with analyst Ken Sena saying he sees "more risk than reward" ahead of Snapchat's anticipated monetization ramp this fall. 2. Ambev (ABEV) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Jeronimo De Guzman saying valuation is full and sees difficult near-term trends ahead given lower disposable income, volume weakness, and lower realized pricing. 3. Icahn Enterprises (IEP) downgraded to Sell from Neutral at UBS saying the company's net asset value, despite declining 49% since second quarter of 2015, seems to include optimistic valuations. 4. Cerulean (CERU) downgraded to Neutral from Buy at Janney Capital, to Market Perform from Outperform at Leerink, and to Market Perform from Outperform at JMP Securities. 5. Magellan Midstream (MMP) downgraded to Underweight at Morgan Stanley with analysts led by Tom Abrams citing a relatively high valuation as the number of lower multiple investment choices has increased. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/18/16
WEDB
08/18/16
DOWNGRADE
WEDB
Neutral
Cerulean downgraded to Neutral from Outperform at Wedbush
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.

TODAY'S FREE FLY STORIES

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:12
10/18/17
10/18
19:12
10/18/17
19:12
Hot Stocks
HP Enterprise raises share buyback by $5B, raises regular dividend 15% »

Given HPE's strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:11
10/18/17
10/18
19:11
10/18/17
19:11
Hot Stocks
HPE to simplify organizational structure, to drive cost savings of $1.5B »

HPE President Antonio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:10
10/18/17
10/18
19:10
10/18/17
19:10
Earnings
HP Enterprise sees FY17 adjusted EPS view roughly $1.00, consensus $1.40 »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

HPE

HP Enterprise

$14.70

0.09 (0.62%)

19:08
10/18/17
10/18
19:08
10/18/17
19:08
Earnings
HP Enterprise sees FY18 adjusted EPS $1.15-$1.25, consensus $1.20 »

HPE expects its non-GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

CME

CME Group

$136.37

0.18 (0.13%)

19:01
10/18/17
10/18
19:01
10/18/17
19:01
Hot Stocks
CME Group, JPX enter agremenet to launch TOPIX futures contract on CME »

CME Group and Japan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

  • 07

    Nov

UAL

United Continental

$67.99

0.48 (0.71%)

18:50
10/18/17
10/18
18:50
10/18/17
18:50
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United Continental sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CSX

CSX

$53.68

-0.55 (-1.01%)

18:49
10/18/17
10/18
18:49
10/18/17
18:49
Hot Stocks
CSX discloses reduction of locomotives in maintenance program »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 30

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:41
10/18/17
10/18
18:41
10/18/17
18:41
Periodicals
Verizon targets spring 2018 start of delayed online TV service, Bloomberg says »

Verizon is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

IBM

IBM

$159.53

12.99 (8.86%)

18:37
10/18/17
10/18
18:37
10/18/17
18:37
Hot Stocks
IBM CFO: Great start to 2H17 »

Says dollar is important…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

SEAS

SeaWorld

$12.31

-0.17 (-1.36%)

18:26
10/18/17
10/18
18:26
10/18/17
18:26
Hot Stocks
SeaWorld to eliminate approximately 350 positions in restructuring program »

On October 18, SeaWorld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

JPM

JPMorgan

$97.99

0.37 (0.38%)

18:12
10/18/17
10/18
18:12
10/18/17
18:12
Hot Stocks
SEC names JPMorgan exec Redfearn Director of Division of Trading and Markets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:10
10/18/17
10/18
18:10
10/18/17
18:10
Periodicals
Verizon targets spring start of delayed online TV service, Bloomberg says »

Verizon web TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:04
10/18/17
10/18
18:04
10/18/17
18:04
Hot Stocks
Steel Dynamics CEO optimistic conditions in place to benefit FY18 consumption »

CEO Mark Millet said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CE

Celanese

$104.03

-0.24 (-0.23%)

18:03
10/18/17
10/18
18:03
10/18/17
18:03
Earnings
Celanese increases price for acetyls and engineered materials products »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:01
10/18/17
10/18
18:01
10/18/17
18:01
Earnings
Steel Dynamics reports Q3 ex-items EPS 66c, consensus 66c »

Reports Q3 revenue $2.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

OPTT

Ocean Power

$2.00

0.56 (38.89%)

17:59
10/18/17
10/18
17:59
10/18/17
17:59
Syndicate
Ocean Power files to sell common stock in 'best efforts' offering »

No amount was provided.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

, TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

17:58
10/18/17
10/18
17:58
10/18/17
17:58
Periodicals
Japan regulators probing Toshiba reporting practices for FY16/17, Nikkei says »

Japan's Securities…

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$87.34

-0.42 (-0.48%)

17:53
10/18/17
10/18
17:53
10/18/17
17:53
Hot Stocks
Pinnacle West raises quarterly divided 6.1% to 69.5c per share »

Pinnacle West…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

GILD

Gilead

$80.01

-0.23 (-0.29%)

17:46
10/18/17
10/18
17:46
10/18/17
17:46
Hot Stocks
FDA grants regulatory approval to Kite's Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 26

    Oct

  • 06

    Nov

  • 12

    Feb

POT

Potash

$19.24

0.08 (0.42%)

, AGU

Agrium

$107.73

0.55 (0.51%)

17:37
10/18/17
10/18
17:37
10/18/17
17:37
Hot Stocks
Potash, Agrium: India approves proposed merger of equals transaction »

Potash Corporation of…

POT

Potash

$19.24

0.08 (0.42%)

AGU

Agrium

$107.73

0.55 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$160.85

1.9 (1.20%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Earnings
Valmont lowers FY17 adjusted EPS view to $6.90-$7.04 from $7.06, consensus $7.09 »

Annual guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NVO

Novo Nordisk

$50.13

0.82 (1.66%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Hot Stocks
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committe »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CHFS

CHF Solutions

$8.30

-0.69 (-7.68%)

17:35
10/18/17
10/18
17:35
10/18/17
17:35
Syndicate
Breaking Syndicate news story on CHF Solutions »

CHF Solutions files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VTGN

VistaGen Therapeutics

$1.31

0.04 (3.15%)

17:33
10/18/17
10/18
17:33
10/18/17
17:33
Syndicate
Breaking Syndicate news story on VistaGen Therapeutics »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

, URI

United Rentals

$144.32

0.98 (0.68%)

17:32
10/18/17
10/18
17:32
10/18/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

URI

United Rentals

$144.32

0.98 (0.68%)

KMI

Kinder Morgan

$18.58

-0.1 (-0.54%)

ADBE

Adobe

$153.00

2.62 (1.74%)

CNAT

Conatus

$5.15

0.05 (0.98%)

EBAY

eBay

$37.97

0.48 (1.28%)

HXL

Hexcel

$58.94

0.39 (0.67%)

CCI

Crown Castle

$100.96

-0.42 (-0.41%)

ESTE

Earthstone Energy

$10.54

-0.15 (-1.40%)

PEGI

Pattern Energy

RXDX

Ignyta

$16.25

1.9 (13.24%)

HCA

HCA Healthcare

$77.45

0.63 (0.82%)

KLAC

KLA-Tencor

$108.09

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 26

    Oct

  • 06

    Nov

  • 06

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    May

  • 16

    May

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.